SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
-8.63%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$604M
AUM Growth
+$604M
(-20%)
Cap. Flow
-$57.3M
Cap. Flow
% of AUM
-9.5%
Top 10 Holdings %
Top 10 Hldgs %
56.78%
Holding
110
New
23
Increased
21
Reduced
26
Closed
29
Top Buys
| 1 |
AstraZeneca
AZN
|
$25.5M |
| 2 |
Merck
MRK
|
$24.1M |
| 3 |
Pfizer
PFE
|
$18M |
| 4 |
AbbVie
ABBV
|
$12.6M |
| 5 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$12M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$21.3M |
| 2 |
Verint Systems
VRNT
|
$16.1M |
| 3 |
Johnson & Johnson
JNJ
|
$11.8M |
| 4 |
Viatris
VTRS
|
$11.3M |
| 5 |
PTC Therapeutics
PTCT
|
$10.3M |
Sector Composition
| 1 | Healthcare | 87.4% |
| 2 | Technology | 6% |
| 3 | Consumer Discretionary | 1.7% |
| 4 | Communication Services | 0.44% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merck
MRK
$210B
| $66.8M | 8.36% | 868,518 +313,518 | +56% | +$24.1M |
|
|
2
Johnson & Johnson
JNJ
$427B
| $45.7M | 5.72% | 348,653 -90,000 | -21% | -$11.8M |
|
3
Bristol-Myers Squibb
BMY
$96B
| $43.5M | 5.44% | 780,000 -135,000 | -15% | -$7.52M |
|
4
Sanofi
SNY
$121B
| $42.4M | 5.3% | 970,000 -170,000 | -15% | -$7.43M |
|
5
Novo Nordisk
NVO
$251B
| $34.7M | 4.34% | 576,000 -64,000 | -10% | -$3.85M |
|
|
6
AstraZeneca
AZN
$248B
| $25.5M | 3.18% | +570,000 | New | +$25.5M |
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $25.2M | 3.16% | 258,000 +118,000 | +84% | +$11.5M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $22.4M | 2.8% | 249,396 +133,683 | +116% | +$12M |
|
9
Amicus Therapeutics
FOLD
$2.34B
| $18.6M | 2.33% | 2,017,624 -782,696 | -28% | -$7.23M |
|
|
10
Pfizer
PFE
$141B
| $18M | 2.25% | +550,000 | New | +$18M |
|
11
Microsoft
MSFT
$3.77T
| $14.8M | 1.85% | 93,964 +35,223 | +60% | +$5.55M |
|
|
12
AbbVie
ABBV
$372B
| $12.6M | 1.57% | +165,000 | New | +$12.6M |
|
13
Novartis
NVS
$245B
| $11.5M | 1.44% | 140,000 -60,000 | -30% | -$4.95M |
|
14
Karyopharm Therapeutics
KPTI
$61.7M
| $10.6M | 1.32% | 550,000 +220,000 | +67% | +$4.23M |
|
15
Amazon
AMZN
$2.44T
| $10.3M | 1.29% | 5,270 +1,570 | +42% | +$3.06M |
|
16
uniQure
QURE
$896M
| $9.54M | 1.19% | 201,107 +61,593 | +44% | +$2.92M |
|
|
CNCE
17
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $8.96M | 1.12% | 1,013,039 +873,039 | +624% | +$7.72M |
|
18
X4 Pharmaceuticals
XFOR
$84.2M
| $8.73M | 1.09% | 873,215 +153,215 | +21% | +$1.53M |
|
19
Allot
ALLT
$362M
| $8.65M | 1.08% | 915,302 -55,364 | -6% | -$523K |
|
20
Y-mAbs Therapeutics
YMAB
$388M
| $8.02M | 1% | 307,379 +94,086 | +44% | +$2.46M |
|
21
Consumers Staples Select Sector SPDR Fund
XLP
$15.8B
| $7.91M | 0.99% | +145,207 | New | +$7.91M |
|
22
Zymeworks
ZYME
$1.12B
| $7.34M | 0.92% | 206,830 +49,830 | +32% | +$1.77M |
|
|
SIOX
23
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $7.15M | 0.89% | 2,931,018 +2,532,477 | +635% | +$6.18M |
|
24
Passage Bio
PASG
$22.7M
| $7.14M | 0.89% | +478,171 | New | +$7.14M |
|
25
Acadia Pharmaceuticals
ACAD
$4.38B
| $6.63M | 0.83% | 157,000 -200,000 | -56% | -$8.45M |
|